Please try another search
For the fiscal year ended 31 December 2021, Life Science Technology Inc revenues increased 100% to W1.21B. Net loss applicable to common stockholders decreased 65% to W603.6M. Revenues reflect Finished Goods Revenues increase from W126.5M to W493.9M, Services Revenue increase from W180.8M to W485.3M. Lower net loss reflects Stock-Based Compensation decrease from W94.4M (expense) to W15.6M (income).
Period Ending: | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 |
---|---|---|---|---|
Total Revenue | 1207.68 | 605.25 | 1067.97 | 229.58 |
Gross Profit | 944.26 | 384.13 | -107.16 | 69.22 |
Operating Income | -650.79 | -1694.58 | -2796.4 | -2926.42 |
Net Income | -597.06 | -1729.27 | -2733.92 | -2400.64 |
Period Ending: | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 |
---|---|---|---|---|
Total Assets | 2696.7 | 4499.87 | 2132.61 | 2014.94 |
Total Liabilities | 2224.32 | 4414.82 | 1412.63 | 1566.71 |
Total Equity | 472.38 | 85.05 | 719.97 | 448.23 |
Period Ending: | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 |
---|---|---|---|---|
Period Length: | 12 Months | 12 Months | 12 Months | 12 Months |
Cash From Operating Activities | 133.66 | -1369.35 | -1484.63 | -2767.46 |
Cash From Investing Activities | -1262.43 | -190.84 | -255.94 | 2343.38 |
Cash From Financing Activities | 966.56 | 975 | 2965.67 | 462.25 |
Net Change in Cash | -162.21 | -585.19 | 1225.1 | 38.18 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review